Clinical trials: Endocrine, Metabolic or Nutritional Diseases or Conditions
Diabetes Mellitus, Type 2, Chronic Kidney Diseases
REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations
Worldwide, diabetic kidney disease (DKD) is the most common cause of chronic and end stage kidney disease. Large-sized prospective randomized clinical trials indicate that intensified glucose and blood pressure control, the…
- Trial name
- REGROUP (NCT04243850)
- Testing
- Empagliflozin 10 MG, Caffeine
- Sponsor
- Amsterdam UMC, location VUmc
Polycystic Ovary Syndrome, Obesity
Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in reproductive age women. PCOS is usually characterized by an excessive androgen production, menstrual irregularities, and polycystic ovaries.
- Trial name
- OMgObPCOS (NCT02521753)
- Testing
- Metformin, Magnesium, PUFA
- Where
- Mexico
- Volunteers
- 123 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Type 2 Diabetes, Overweight and Obese Adults
Effects of D-Chiro-Inositol Combined with Metformin on Insulin Resistance in People with Overweight or Obesity and T2DM
This study evaluates the efficacy of D-Chiro-Inositol (DCI) as an add-on therapy to metformin in improving insulin resistance, measured by the HOMA index, in people with overweight or obesity and type 2 diabetes mellitus (T2DM).
- Trial name
- DIACHIRO (NCT06860841)
- Testing
- D-Chiro-Inositol Combined with Metformin
- Where
- Italy
- Volunteers
- 16 people
- Sponsor
- Campus Bio-Medico University
Obesity, Overweight
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes.
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Trial name
- NCT07215559
- Testing
- Macupatide, Eloralintide
- Where
- 42 sites in United States, Argentina and 2 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Gingivitis, Diabetes
Mechanical-chemical Gingival Therapy in Diabetics and/or Obese
Diabetes and obesity affect many people in different countries. Similarly, millions of people have some type of gum disease such as gingivitis.
- Conditions
- Gingivitis, Diabetes, Obesity
- Trial name
- MCGTDO (NCT02123563)
- Testing
- Ultrason Essential oils rinse
- Where
- Brazil
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Taubate
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2
The aim of this study is to investigate the relationship between body fat distribution measured by CT scan and related risk factors with the risk of incident metabolic and cardiovascular disease in a prospective cohort study of…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes, Diabetes Mellitus, Hypertension
- Trial name
- OCES-2 (NCT06694012)
- Where
- Japan
- Volunteers
- 2,000 people
- Sponsor
- Osaka Metropolitan University
Type2 Diabetes, Weight Loss
Improving Glucose and Lipid Metabolism Through Caloric Restriction Using Diet or Surgery (CRUDOS)
In this explorative randomized clinical study, the investigators aim to study metabolic, cellular, and molecular changes that occur during weight loss in obese subjects with and without type 2 diabetes.
- Conditions
- Type2 Diabetes, Weight Loss, Insulin Sensitivity, Metabolism and Nutrition Disorder
- Trial name
- CRUDOS (NCT02988011)
- Testing
- Gastric by-pass surgery, Low-caloric diet
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Uppsala University
Healthy, Overweight and Obesity
Strategies To OPpose Sugars With Non-nutritive Sweeteners Or Water (STOP Sugars NOW) Trial
Health authorities recommend a reduction in added sugars from sugar-sweetened beverages (SSBs) due to risk of obesity and diabetes. As a sugar-reduction strategy, finding the ideal SSB replacement is of the utmost importance.
- Conditions
- Healthy, Overweight and Obesity, Metabolic Syndrome, PreDiabetes
- Trial name
- NCT03543644
- Testing
- Sugar-sweetened beverage (SSB), Non-nutritive sweetened beverages (NSB), Water
- Where
- Canada
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- ENLIGHTEN-10 (NCT07900633)
- Testing
- Eloralintide
- Where
- 309 sites in United States, Argentina and 19 more
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company
Hypertension, Obesity
Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients
The goal of this study is to build a mathematical model to explain the effect of two doses of azilsartan (40 and 80 mg) upon metabolic (insulin resistance, glucose) and inflammatory parameters (cytokines) in function of…
- Conditions
- Hypertension, Obesity, Type 2 Diabetes Mellitus
- Trial name
- NCT02235519
- Testing
- Azilsartan 40 mg., Azilsartan 80 mg
- Where
- Mexico
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Diabetes (DM), Diabete Mellitus
Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
Mental conditions and disorders (e.g. distress, depressive, anxiety, and eating disorders) are more prevalent in people with diabetes (PWD) and associated with reduced quality of life and impaired glycaemic outcomes.
- Conditions
- Diabetes (DM), Diabete Mellitus, Diabete Type 1, Diabete Type 2
- Trial name
- TwinPeaks (NCT07212075)
- Where
- 3 sites in Germany
- Volunteers
- 1,809 people
- Sponsor
- Forschungsinstitut der Diabetes Akademie Mergentheim
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Diabetes Mellitus, Insulin Resistance
Insulin Infusion Diabetes Ulcer
Normoglycemia is important for the outcome of surgical and medical conditions. Insulin infusions have been studied to achieve normoglycemia during these circumstances and have proved to be useful.
- Conditions
- Diabetes Mellitus, Insulin Resistance, Hyperglycemia, Surgery
- Trial name
- IINDU (NCT00700154)
- Testing
- Insulin infusion
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Karolinska Institutet
Obesity, Obesity; Endocrine
Probiotic Blend in Reducing Anthropometric Measurements in Obese Adults
It is already known that dysbiosis, that is, qualitative and quantitative changes in the composition of the intestinal microbiota, can be associated with the development of a series of intestinal and extra-intestinal disorders.
- Conditions
- Obesity, Obesity; Endocrine, Overweight and Obesity, Overweight, Obesity and Other Hyperalimentation
- Trial name
- NCT05676229
- Testing
- Probiotic blend
- Where
- Brazil
- Volunteers
- 108 people
- Sponsor
- Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude
Type 2 Diabetes Mellitus
Relationship Between Body Weight and Glycohemoglobin
Control of body weight (BW) is important to prevent and manage type 2 diabetes. Regardless of the close association, little is understood about the precise relationship between BW and glycemic control, which might be of benefit…
- Trial name
- NCT00892372
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Saitama Medical University
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to…
- Trial name
- CONFIDENCE (NCT05254002)
- Testing
- Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Finerenone (BAY94-8862 ) 20 mg
- Where
- 173 sites in United States, Belgium and 12 more
- Volunteers
- 1,664 people
- Sponsor
- Bayer
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Glucose Intolerance, Hyperinsulinemia
Health Effects of Liposuction in Overweight Women With Elevated Insulin Levels, Impaired Glucose Tolerance and/or Type 2 Diabetes
This study is for women who have already decided to undergo liposuction at Georgetown University Medical Center in Washington, D.C.
- Conditions
- Glucose Intolerance, Hyperinsulinemia, Diabetes Mellitus, Non Insulin Dependent, Obesity
- Trial name
- NCT00005760
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)